Candida, Bacterial Vaginosis + Urinary Tract Infections

Clinically, GR-1 suppresses Candida growth by 52 - 73%, blocks fungal metabolism and biofilm formation, improves bacterial vaginosis (BV) culture results in 59% of women, and, when paired with antimicrobial treatment normalises BV markers in 88% versus 40% with placebo. In recurrent UTI populations, daily GR-1 + RC-14 lowers infection frequency from 6.8 to 3.3 UTIs per year.

Lactobacillus reuteri RC-14 works synergistically with GR-1, adhering to the vaginal epithelium and producing lactic acid, hydrogen peroxide, and bacteriocins that inhibit E. coli, Candida albicans, and BV-related anaerobes while preventing pathogenic attachment. Clinical trials consistently show that GR-1 + RC-14 increases vaginal Lactobacillus counts, normalises microbiome swabs in 90% of women, and restores healthy flora in 61.2% versus 26.85% using placebo.[14][15][17][21]

Supplement